BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances.
Chinese hamster ovary (CHO) cells are a common and stable option for mammalian expression systems, but what are the other cell line options in upstream processing and how do they compare in quality and stability to CHO cells? And what are the best techniques for ensuring quality and stability in cell-line development? BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances and the analytical techniques companies can use to ensure quality and stability.
Download the BioPharm International
Bioprocessing Trends 2016 eBook.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.